Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708946 | 1.00 | NPC1 (0.64) | NPC1RAB9AMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL16915473 | 0.98 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL16915472 | 0.98 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL29167691 | 0.85 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL29167694 | 0.85 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28360788 | 0.83 | NFKB1 (0.71) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL9791652 | 0.82 | RAB9A (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL9791651 | 0.82 | RAB9A (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL16915457 | 0.82 | RAB9A (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL16915466 | 0.82 | TRPA1 (0.55) | NPC1MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190187557-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PLATE-MAKING METHOD USING SAME | FUJIFILM CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| EP-3094625-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| EP-0347800-B1 | Toner for electrostatic images | MITSUBISHI GAS CHEMICAL CO (JP) | 1995-02-22 | — | — | EP | disclosed |
| EP-0290860-B1 | Thermosetting resin composition | MITSUBISHI GAS CHEMICAL CO (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0559695-A1 | NEW PYRIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS. | BOEHRINGER MANNHEIM GMBH (DE) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009598-A1 | NEW PYRIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1992-06-11 | — | — | WO | disclosed |
| US-4945138-A | Styrylaza vinyl esters | THE DOW CHEMICAL COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| US-4904760-A | HEAT AND CHEMICAL RESISTANCE LOW DIELECTRIC | MITSUBISHI GAS CHEMICAL CO., INC. (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0347800-A2 | Toner for electrostatic images | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4883844-A | FROM AROMATIC ALDEHYDE AND SUBSTITUTED PYRIDINE | THE DOW CHEMICAL COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
| US-4851483-A | FROM EPOXIDIZED HYDROXYSTYRYLAZA COMPOUNDS DERIVED FROM AROMATIC HYDROXYALDEHYDES AND METHYLATED PYRIDINES OR PYRAZINES | THE DOW CHEMICAL COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0290860-A2 | Thermosetting resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | NPC1 2934/4885RAB9A 4667/4885MEN1 4500/4885 |
| US-20160326122-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, FLT1 | NPC1 3155/4885RAB9A 1177/4885MEN1 3923/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | NPC1 1960/4885RAB9A 4089/4885MEN1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.